Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL)
Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL)
General News
Home >> News >> General News
GRMH-GDL Held Laboratory Building Opening & CUHK-GDL Advanced Institute for Regenerative Medicine Construction Launching Ceremony
Release time:2019-09-23

On 22nd September, Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL) held the Laboratory Building opening and CUHK- GDL Advanced Institute for Regenerative Medicine (CUHK- GDL AIRM) construction launching ceremony.

Professor Duanqing Pei, Vice Excutive Director of GDL, made welcome speech on ceremony. He said that started from scratch, GRMH-GDL completed its park construction with more than one year’s effort,  and now it is officially put to use, this is a significant step in development. He then expressed gratitude to all the units and people from different field for their support during construction.


GRMH-GDL was founded on 22nd December 2017 as one of the first provincial laboratories to develop the reserves for constructing national laboratories in Guangdong Province and operated as a public institution. GRMH-GDL is supported by the Guangzhou Institutes of Biomedicine and Health (GIBH),Chinese Academy of Sciences (CAS), joining hands with superior scientific research units in Guangdong, Hong Kong and Macao and top international scientific research forces, to address major strategic needs of Guangdong Province and the whole country. It dedicates to 4 directions: frontier theoretical and technological research on stem cells and regenerative medicine, research on remodeling of tissues and organs, precision medicine & preclinical study, and research on the application of regenerative medicine.

The gross area of the laboratory building reached over 11000 square meters, enabling more than 200 reasearchers to work in international standard laboratories.

It is learned that the institute will focus on fields of stem cell biology, regenerative medicine, tissue engineering, tissue and organ reconstruction, precision medicine, preclinical research and regenerative application; at the same time, it will promote the process of basic research to clinical transfer, and establish platforms to develop innovative therapy for public benefit.

Latest News